What does the drug do?
ILB is a pleiotropic molecule which means it is believed to have multiple effects in the body. Its active component, a patented form of dextran sulphate, targets multiple pathways that are involved in the loss of function and death of neurons, which is characteristic of MND and other neurological diseases. It is administered via a subcutaneous (under-the-skin) injection.
Trial Outcome
The Phase 2 open label trial was stopped early due to the COVID-19 pandemic. 11 participants were enrolled into the study and took 2 mg/kg of ILB, by subcutaneous (under the skin) injection, once a week for up to 38 weeks. The trial found weekly ILB injections to be safe and well tolerated. Further research is needed to understand any potential benefit ILB may have for people with MND. You can read more about the trial here or in a pre-print article (please note pre-prints articles have not been peer reviewed).
Clinical Trials
Phase 2
The Phase 2 open label trial investigated the safety and tolerability of ILB in 11 participants. The participants took 2 mg/kg of ILB, by subcutaneous (under the skin) injection once a week for up to 38 weeks. Due to the COVID-19 pandemic, recruitment and treatment was suspended in early 2020, meaning the trial was stopped early. The trial found weekly ILB injections to be safe and well tolerated. You can read more about the trial here or in a pre-print article (please note pre-prints articles have not been peer reviewed).
Latest News
2022
May 2022 - TikoMed announce results from a Swedish trial of ILB that show some improvement in ALSFRS-R scores and decreased levels of biomarkers associated with muscle wasting. Results from the UK trial are expected in 2023. You can find out more here.
Last updated: 10/04/2024